research

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Authors
Publication date
1 January 2017
Publisher
Springer Nature
Doi
    View on PubMed

    Abstract

    Change from baseline in swollen (a) and tender (b) joint counts. *Error bars show upper SE for placebo and lower SE for namilumab. SE standard error, SJC swollen joint count, TJC tender joint count. (PDF 1292 kb

      Similar works

      Full text

      thumbnail-image

      Available Versions

      NARCIS

      redirect
      Last time updated on 29/05/2021

      Crossref

      redirect
      oaiinfo:doi/10.1186%2Fs13075-017-...
      Last time updated on 05/06/2019

      The Francis Crick Institute

      redirect
      oaioai:figshare.com:article/47367...
      Last time updated on 12/02/2018

      Springer - Publisher Connector

      redirect
      Last time updated on 04/06/2019

      Leiden University Scholary Publications

      redirect
      oaioai:scholarlypublications.univ...
      Last time updated on 12/03/2021

      Springer - Publisher Connector

      redirect
      Last time updated on 30/04/2017

      The Francis Crick Institute

      redirect
      oaioai:figshare.com:article/47368...
      Last time updated on 12/02/2018